Physician profile
David E Karas
NPI 1386604296
$31,425.11
in general payments reported to CMS, 2019-2025
5 companies · $6,422 in 2025
The $6,422 reported for 2025 was more than what 92% of Sleep Medicine (Pediatrics) providers received nationally (typical 2025 total: $235).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,493 · 2020: $1,736 · 2021: $7,573 · 2022: $622 · 2023: $6,819 · 2024: $1,760 · 2025: $6,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $3,342 · Food and Beverage: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,408.88 |
| Travel and Lodging | $3,341.54 |
| Food and Beverage | $250.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $24,735.52 | 2020-2025 | Elaprase |
| Shire North American Group INC | $6,478.58 | 2019 | |
| Medtronic, INC. | $185.66 | 2023-2025 | Sinuva, Propel, Nuvent |
| Novartis Pharmaceuticals Corporation | $14.17 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Karas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.